Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in part explained by the gain of a secondary EGFR mutation, T790M, at the ga...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Ercan, Dalia, Zejnullahu, Kreshnik, Yonesaka, Kimio, Xiao, Yun, Capelletti, Marzia, Rogers, Andrew, Lifshits, Eugene, Brown, Alison, Lee, Charles, Christensen, James G., Kwiatkowski, David J., Engelman, Jeffrey A., Jänne, Pasi A.
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2859699/
https://ncbi.nlm.nih.gov/pubmed/20118985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2009.526
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker